{"id":460,"date":"2025-12-02T15:29:17","date_gmt":"2025-12-02T15:29:17","guid":{"rendered":"https:\/\/solfed.fr\/?p=460"},"modified":"2025-12-02T15:29:18","modified_gmt":"2025-12-02T15:29:18","slug":"cancer-medullaire-de-la-thyroide-ce-que-revelent-43-ans-de-donnees-du-registre-marne-ardennes","status":"publish","type":"post","link":"https:\/\/solfed.fr\/?p=460","title":{"rendered":"Cancer m\u00e9dullaire de la thyro\u00efde : ce que r\u00e9v\u00e8lent 43 ans de donn\u00e9es du registre Marne-Ardennes"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Cancer m\u00e9dullaire de la thyro\u00efde : ce que montrent plus de 40 ans de donn\u00e9es fran\u00e7aises<\/strong><\/h2>\n\n\n\n<p>Le cancer m\u00e9dullaire de la thyro\u00efde (CMT) est une forme rare de cancer thyro\u00efdien, repr\u00e9sentant une faible proportion de l\u2019ensemble des tumeurs de la glande. Gr\u00e2ce au registre Marne-Ardennes, qui collecte les donn\u00e9es depuis 1975, il est aujourd\u2019hui possible d\u2019avoir une id\u00e9e plus pr\u00e9cise de son \u00e9volution, de ses caract\u00e9ristiques et de son pronostic.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Une maladie rare mais mieux identifi\u00e9e<\/strong><\/h2>\n\n\n\n<p>Sur la p\u00e9riode \u00e9tudi\u00e9e, pr\u00e8s de 300 patients atteints de CMT ont \u00e9t\u00e9 recens\u00e9s. Contrairement au cancer papillaire \u2014 de loin le plus fr\u00e9quent \u2014 le CMT reste stable dans le temps, m\u00eame si sa fr\u00e9quence a l\u00e9g\u00e8rement augment\u00e9 ces derni\u00e8res d\u00e9cennies.<\/p>\n\n\n\n<p>Une partie des cas (environ 20 \u00e0 25 %) est li\u00e9e \u00e0 une mutation h\u00e9r\u00e9ditaire des g\u00e8nes RET. Cette d\u00e9couverte a renforc\u00e9 l\u2019importance du d\u00e9pistage g\u00e9n\u00e9tique dans les familles \u00e0 risque.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Des caract\u00e9ristiques particuli\u00e8res<\/strong><\/h2>\n\n\n\n<p>Le CMT ne se comporte pas comme les autres cancers thyro\u00efdiens. Il provient des cellules C parafolliculaires et se distingue par sa s\u00e9cr\u00e9tion de calcitonine, un marqueur essentiel pour le diagnostic et le suivi.<\/p>\n\n\n\n<p>Les donn\u00e9es du registre montrent que :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>certains cas sont diagnostiqu\u00e9s \u00e0 un stade m\u00e9tastatique ;<\/li>\n\n\n\n<li>l\u2019atteinte ganglionnaire au diagnostic influence nettement le pronostic ;<\/li>\n\n\n\n<li>les formes sporadiques (non h\u00e9r\u00e9ditaires) sont souvent d\u00e9couvertes plus tard, avec un impact n\u00e9gatif sur la survie.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Pronostic et facteurs influents<\/strong><\/h2>\n\n\n\n<p>La survie est globalement bonne, mais inf\u00e9rieure \u00e0 celle des cancers thyro\u00efdiens d\u2019origine folliculaire. Les analyses montrent clairement que :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>la pr\u00e9sence de m\u00e9tastases au diagnostic diminue la survie ;<\/li>\n\n\n\n<li>l\u2019atteinte ganglionnaire est un facteur p\u00e9joratif important ;<\/li>\n\n\n\n<li>les patients ayant une forme h\u00e9r\u00e9ditaire rep\u00e9r\u00e9e t\u00f4t peuvent b\u00e9n\u00e9ficier d\u2019un traitement plus efficace.<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Prise en charge : l\u2019importance de l\u2019expertise<\/strong><\/h2>\n\n\n\n<p>Le traitement repose principalement sur la chirurgie. La thyro\u00efdectomie totale associ\u00e9e \u00e0 un curage ganglionnaire central reste aujourd\u2019hui <strong>le seul traitement curatif<\/strong>.<br>Pour garantir de meilleurs r\u00e9sultats, il est recommand\u00e9 d\u2019\u00eatre pris en charge dans un centre sp\u00e9cialis\u00e9, avec un chirurgien exp\u00e9riment\u00e9 dans les cancers thyro\u00efdiens rares.<\/p>\n\n\n\n<p>Les formes avanc\u00e9es ou m\u00e9tastatiques n\u00e9cessitent une prise en charge multidisciplinaire incluant oncologues, endocrinologues et chirurgiens sp\u00e9cialis\u00e9s. Les th\u00e9rapies cibl\u00e9es jouent d\u00e9sormais un r\u00f4le dans certaines situations complexes.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>\u00c0 retenir<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Le CMT est une maladie <strong>rare<\/strong>, mais mieux comprise gr\u00e2ce aux registres de cancer.<\/li>\n\n\n\n<li>Son diagnostic repose sur la calcitonine, la cytologie et le d\u00e9pistage g\u00e9n\u00e9tique.<\/li>\n\n\n\n<li>La chirurgie constitue le traitement curatif central.<\/li>\n\n\n\n<li>Les formes h\u00e9r\u00e9ditaires repr\u00e9sentent <strong>un quart des cas<\/strong>.<\/li>\n\n\n\n<li>Le pronostic d\u00e9pend fortement du stade au moment du diagnostic et de la pr\u00e9sence ou non de m\u00e9tastases.<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cancer m\u00e9dullaire de la thyro\u00efde : ce que montrent plus de 40 ans de donn\u00e9es fran\u00e7aises Le cancer m\u00e9dullaire de la thyro\u00efde (CMT) est une forme rare de cancer thyro\u00efdien, repr\u00e9sentant une faible proportion de l\u2019ensemble des tumeurs de la glande. Gr\u00e2ce au registre Marne-Ardennes, qui collecte les donn\u00e9es depuis 1975, il est aujourd\u2019hui possible [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[14],"tags":[],"class_list":["post-460","post","type-post","status-publish","format-standard","hentry","category-14"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cancer m\u00e9dullaire de la thyro\u00efde : ce que r\u00e9v\u00e8lent 43 ans de donn\u00e9es du registre Marne-Ardennes - Solfed<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/solfed.fr\/?p=460\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cancer m\u00e9dullaire de la thyro\u00efde : ce que r\u00e9v\u00e8lent 43 ans de donn\u00e9es du registre Marne-Ardennes - Solfed\" \/>\n<meta property=\"og:description\" content=\"Cancer m\u00e9dullaire de la thyro\u00efde : ce que montrent plus de 40 ans de donn\u00e9es fran\u00e7aises Le cancer m\u00e9dullaire de la thyro\u00efde (CMT) est une forme rare de cancer thyro\u00efdien, repr\u00e9sentant une faible proportion de l\u2019ensemble des tumeurs de la glande. Gr\u00e2ce au registre Marne-Ardennes, qui collecte les donn\u00e9es depuis 1975, il est aujourd\u2019hui possible [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/solfed.fr\/?p=460\" \/>\n<meta property=\"og:site_name\" content=\"Solfed\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-02T15:29:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-02T15:29:18+00:00\" \/>\n<meta name=\"author\" content=\"fouadnassarx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"fouadnassarx\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/solfed.fr\/?p=460#article\",\"isPartOf\":{\"@id\":\"https:\/\/solfed.fr\/?p=460\"},\"author\":{\"name\":\"fouadnassarx\",\"@id\":\"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#\/schema\/person\/45018b9be6f3a9994cdd3cc8af14e522\"},\"headline\":\"Cancer m\u00e9dullaire de la thyro\u00efde : ce que r\u00e9v\u00e8lent 43 ans de donn\u00e9es du registre Marne-Ardennes\",\"datePublished\":\"2025-12-02T15:29:17+00:00\",\"dateModified\":\"2025-12-02T15:29:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/solfed.fr\/?p=460\"},\"wordCount\":517,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#organization\"},\"articleSection\":[\"2025\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/solfed.fr\/?p=460#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/solfed.fr\/?p=460\",\"url\":\"https:\/\/solfed.fr\/?p=460\",\"name\":\"Cancer m\u00e9dullaire de la thyro\u00efde : ce que r\u00e9v\u00e8lent 43 ans de donn\u00e9es du registre Marne-Ardennes - Solfed\",\"isPartOf\":{\"@id\":\"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#website\"},\"datePublished\":\"2025-12-02T15:29:17+00:00\",\"dateModified\":\"2025-12-02T15:29:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/solfed.fr\/?p=460#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/solfed.fr\/?p=460\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/solfed.fr\/?p=460#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/solfed.fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cancer m\u00e9dullaire de la thyro\u00efde : ce que r\u00e9v\u00e8lent 43 ans de donn\u00e9es du registre Marne-Ardennes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#website\",\"url\":\"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/\",\"name\":\"Solfed\",\"description\":\"Renforce les liens scientifiques, organise des congr\u00e8s annuels et partage des ressources de r\u00e9f\u00e9rence en endocrinologie et diab\u00e9tologie.\",\"publisher\":{\"@id\":\"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#organization\",\"name\":\"Solfed\",\"url\":\"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/solfed.fr\/wp-content\/uploads\/2025\/09\/logo.png\",\"contentUrl\":\"https:\/\/solfed.fr\/wp-content\/uploads\/2025\/09\/logo.png\",\"width\":660,\"height\":204,\"caption\":\"Solfed\"},\"image\":{\"@id\":\"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#\/schema\/person\/45018b9be6f3a9994cdd3cc8af14e522\",\"name\":\"fouadnassarx\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4fa4781b79e3e17b649b4d8cbaff803e4bfa39a9694e50f8454641b09df11a79?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4fa4781b79e3e17b649b4d8cbaff803e4bfa39a9694e50f8454641b09df11a79?s=96&d=mm&r=g\",\"caption\":\"fouadnassarx\"},\"sameAs\":[\"https:\/\/solfed.fr\"],\"url\":\"https:\/\/solfed.fr\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cancer m\u00e9dullaire de la thyro\u00efde : ce que r\u00e9v\u00e8lent 43 ans de donn\u00e9es du registre Marne-Ardennes - Solfed","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/solfed.fr\/?p=460","og_locale":"en_US","og_type":"article","og_title":"Cancer m\u00e9dullaire de la thyro\u00efde : ce que r\u00e9v\u00e8lent 43 ans de donn\u00e9es du registre Marne-Ardennes - Solfed","og_description":"Cancer m\u00e9dullaire de la thyro\u00efde : ce que montrent plus de 40 ans de donn\u00e9es fran\u00e7aises Le cancer m\u00e9dullaire de la thyro\u00efde (CMT) est une forme rare de cancer thyro\u00efdien, repr\u00e9sentant une faible proportion de l\u2019ensemble des tumeurs de la glande. Gr\u00e2ce au registre Marne-Ardennes, qui collecte les donn\u00e9es depuis 1975, il est aujourd\u2019hui possible [&hellip;]","og_url":"https:\/\/solfed.fr\/?p=460","og_site_name":"Solfed","article_published_time":"2025-12-02T15:29:17+00:00","article_modified_time":"2025-12-02T15:29:18+00:00","author":"fouadnassarx","twitter_card":"summary_large_image","twitter_misc":{"Written by":"fouadnassarx","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/solfed.fr\/?p=460#article","isPartOf":{"@id":"https:\/\/solfed.fr\/?p=460"},"author":{"name":"fouadnassarx","@id":"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#\/schema\/person\/45018b9be6f3a9994cdd3cc8af14e522"},"headline":"Cancer m\u00e9dullaire de la thyro\u00efde : ce que r\u00e9v\u00e8lent 43 ans de donn\u00e9es du registre Marne-Ardennes","datePublished":"2025-12-02T15:29:17+00:00","dateModified":"2025-12-02T15:29:18+00:00","mainEntityOfPage":{"@id":"https:\/\/solfed.fr\/?p=460"},"wordCount":517,"commentCount":0,"publisher":{"@id":"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#organization"},"articleSection":["2025"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/solfed.fr\/?p=460#respond"]}]},{"@type":"WebPage","@id":"https:\/\/solfed.fr\/?p=460","url":"https:\/\/solfed.fr\/?p=460","name":"Cancer m\u00e9dullaire de la thyro\u00efde : ce que r\u00e9v\u00e8lent 43 ans de donn\u00e9es du registre Marne-Ardennes - Solfed","isPartOf":{"@id":"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#website"},"datePublished":"2025-12-02T15:29:17+00:00","dateModified":"2025-12-02T15:29:18+00:00","breadcrumb":{"@id":"https:\/\/solfed.fr\/?p=460#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/solfed.fr\/?p=460"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/solfed.fr\/?p=460#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/solfed.fr\/"},{"@type":"ListItem","position":2,"name":"Cancer m\u00e9dullaire de la thyro\u00efde : ce que r\u00e9v\u00e8lent 43 ans de donn\u00e9es du registre Marne-Ardennes"}]},{"@type":"WebSite","@id":"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#website","url":"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/","name":"Solfed","description":"Renforce les liens scientifiques, organise des congr\u00e8s annuels et partage des ressources de r\u00e9f\u00e9rence en endocrinologie et diab\u00e9tologie.","publisher":{"@id":"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#organization","name":"Solfed","url":"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/solfed.fr\/wp-content\/uploads\/2025\/09\/logo.png","contentUrl":"https:\/\/solfed.fr\/wp-content\/uploads\/2025\/09\/logo.png","width":660,"height":204,"caption":"Solfed"},"image":{"@id":"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#\/schema\/person\/45018b9be6f3a9994cdd3cc8af14e522","name":"fouadnassarx","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/solfed-bc8f75.ingress-daribow.ewp.live\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4fa4781b79e3e17b649b4d8cbaff803e4bfa39a9694e50f8454641b09df11a79?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4fa4781b79e3e17b649b4d8cbaff803e4bfa39a9694e50f8454641b09df11a79?s=96&d=mm&r=g","caption":"fouadnassarx"},"sameAs":["https:\/\/solfed.fr"],"url":"https:\/\/solfed.fr\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/solfed.fr\/index.php?rest_route=\/wp\/v2\/posts\/460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/solfed.fr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/solfed.fr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/solfed.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/solfed.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=460"}],"version-history":[{"count":1,"href":"https:\/\/solfed.fr\/index.php?rest_route=\/wp\/v2\/posts\/460\/revisions"}],"predecessor-version":[{"id":462,"href":"https:\/\/solfed.fr\/index.php?rest_route=\/wp\/v2\/posts\/460\/revisions\/462"}],"wp:attachment":[{"href":"https:\/\/solfed.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/solfed.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/solfed.fr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}